anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During premarket evaluation, seizure was identified as the most significant risk of clomipramine use. 

The observed cumulative incidence of seizures among patients exposed to clomipramine at doses up to 300 mg/day was 0.64% at 90 days, 1.12% at 180 days, and 1.45% at 365 days. The cumulative rates correct the crude rate of 0.7% (25 of 3519 patients) for the variable duration of exposure in clinical trials. 

Although dose appears to be a predictor of seizure, there is a confounding of dose and duration of exposure, making it difficult to assess independently the effect of either factor alone. The ability to predict the occurrence of seizures in subjects exposed to doses of CMI greater than 250 mg is limited, given that the plasma concentration of CMI may be dose-dependent and may vary among subjects given the same dose. Nevertheless, prescribers are advised to limit the daily dose to a maximum of 250 mg in adults and 3 mg/kg (or 200 mg) in children and adolescents (see DOSAGE AND ADMINISTRATION). 

Caution should be used in administering clomipramine to patients with a history of seizures or other predisposing factors, e.g., brain damage of varying etiology, alcoholism, and concomitant use with other drugs that lower the seizure threshold. 

Rare reports of fatalities in association with seizures have been reported by foreign postmarketing surveillance, but not in U.S. clinical trials. In some of these cases, clomipramine had been administered with other epileptogenic agents; in others, the patients involved had possibly predisposing medical conditions. Thus a causal association between clomipramine treatment and these fatalities has not been established. 

Physicians should discuss with patients the risk of taking clomipramine while engaging in activities in which sudden loss of consciousness could result in serious injury to the patient or others, e.g., the operation of complex machinery, driving, swimming, climbing.
Statin treatment improves coronary flow reserve (CFR) and decreases cardiac morbidity and mortality in patients with coronary artery disease (CAD) and hypercholesterolemia. Endothelial dysfunction and impairment in coronary microcirculation is also observed in hypertensive patients with cardiovascular risk factors. However, the measurement of CFR has rarely been performed in hypertensive patients without CAD, because CFR could be invasively measured using a Doppler guide wire in a cardiac catheterization laboratory. Recent advances in echocardiographic imaging techniques have made it possible to measure coronary flow velocity and CFR, which highly correlates with the CFR measured by invasive means.

Lipid lowering with a statin provided beneficial effects in patients with average levels of serum total cholesterol in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) study conducted in hypertensive patients at cardiovascular risk. Improvements in endothelial dysfunction and CFR may be related to the beneficial effects of statins in hypertensive patients without hypercholesterolemia, but the effect of statins on CFR has not been examined in such patients. Accordingly, the investigators try to examine the hypothesis that pitavastatin added to standard antihypertensive therapy in hypertensive patients with cardiovascular risk will be superior to placebo in improving CFR in a double-blind, randomized comparison study using Doppler echocardiography.
PURPOSE:To obtain a promoter of hydrolase activities capable of becoming a promoter of blood coagulation, promoting activities of protease, especially thrombin, trypsin, etc., containing a cyclic organic compound. CONSTITUTION:A promoter of hydrolase activity containing a compound shown by the formula (R<1> is residue of cyclic compound). The hydrolase is an enzyme capable of hydrolyzing a bond between Arg and an arbitrary amino acid residue and/or a bond between Lys and an arbitrary amino acid residue. The promoter of hydrolase activities by itself has no promoting action on blood coagulation but combination of the promoter with an enzyme promotes coagulation of blood and coagulates blood in a short time. Since the promoter of hydrolase activities does not change a serum component, examination values of various kinds of tests using serum can be accurately and stably measured. When containers for blood examination having the promoter of blood coagulation are prepared, blood tests can be simply carried out.
Viruses and viral diseases are controlled in humans and animals by treatment with nucleases (I) isolated from bovine pancreas. (I) also include ribonucleases and deoxyribonucleases, specifically DNaseI. USE/ADVANTAGE - (I) are able to inhibit activity of viruses in humans or animals, and are effective against all viral diseases. Also (I) are rapidly broken down in the liver and do not harm the host. In an example rodents having a limited, ectodermal infection with herpes virus were treated with an ointment contg. 30000 ppm (I). After 3 repeat applications, the treated regions were free of virus.
Motor Neurone Disease (MND) is neurodegenerative disorder that leads to progressive weakness of limb, bulbar and respiratory muscles. The most common form of the disease is the Amyotrophic Lateral Sclerosis (ALS). Severe weakness of the neck extensor muscles is common in patients with ALS. Those patients are advised to wear a cervical collar, to improve their neck posture and social interaction. However the main limit of commercially available collars is that they are designed to immobilize the neck, which makes them uncomfortable and strenuous to wear for long time. The aim of this study is to evaluate the effects on MND patients of a new collar specifically designed for people affected by neck weakness: the Sheffield Support Snood. The assessment will be performed through the use of inertial sensors since they allow the measurement to be performed in real life settings (clinics/home) with reduced discomfort to the patient. Subjects will be asked to perform a series of active head movements (flexion, extension, axial rotation, lateral bending) with and without the collar and the range of movement measured in the two cases will be used to assess the support offered by the collar. Since in MND patients difficulty in perform active head movements is due to a severe weakness of the extensor muscles, with or without involvement of the neck flexors, this study will also investigate the activation of these muscles while the subject is performing the active head movements. A wireless surface electromyographic system (sEMG) will be used to this purpose. Patients able to perform a series of activities of daily living (ADL, ie: drinking, eating, washing hands) will be asked to perform the tasks both with and without the collar. The support perceived by the subjects while they are performing the ADL will be evaluated through a questionnaire specifically developed for this study.
The invention provides zinnia whitening foot bath powder and a preparation method thereof. Every 35 g of zinnia whitening foot bath powder is prepared from 20 g of traditional Chinese medicine mixed powder and 15 g of traditional Chinese medicine mixed residues. Every 20 g of traditional Chinese medicine mixed powder is prepared from zinnia, physalis alkekengi, chaulmoogratree seeds, rhizoma nardostachyos, ginkgos, kelp, fructus lycii, duckweed, Scutellaria indica and watermelon peel in the proportion of 10:(5-8):(4-7):(4-6):(3-5):(2-4):(2-3):(1-3):(2-3):(1-2). Every 15 g of traditional Chinese medicine mixed residues is obtained after the raw materials in 20 g of traditional Chinese medicine mixed powder are processed. The preparation method includes the steps that firstly, the raw materials are preprocessed; secondly, ultrasonic extraction is conducted; thirdly, concentration and drying are conducted; fourthly, smashing and sterilization are conducted. According to the zinnia whitening foot bath powder and the preparation method thereof, the preparation technology is simple and scientific, and the prepared foot bath powder is convenient to use, remarkable in treatment effect and good in whitening effect.
The invention comprises compounds of the formula  <FORM:0877495/IV (b)/1> wherein R represents a hydrogen atom or an alkyl group, and the preparation thereof by diazotizing 3-amino-2,4,6-triiodobenzoic acid or an alkyl ester thereof and treating the diazonium salt thus obtained with a metallic iodide.  The invention also includes X-ray contrast media containing the products (see Group VI).  The compound in which R represents hydrogen may, if desired, be esterified to yield the compound in which R represents an alkyl group.  Methyl 3-amino-2,4,6-triiodobenzoate is prepared by appropriate esterification.  2,3,4,6-Tetraiodobenzoic acid chloride is prepared by treating the appropriate acid with phosphorus pentachloride and phosphorus oxychloride.ALSO:X-ray contrast media comprise at least one of the compounds having the general formula <FORM:0877495/VI/1> (in which R represents a hydrogen atom or an alkyl group) with appropriate carriers.  An example describes a suspension of methyl-2,3,4,6-tetraiodobenzoate in arachis oil for use in bronchography.
The current phase of the study is an open-label dose-finding phase in which critically injured children undergo prospective, serial immune function testing in the first few days after injury. If a subject's immune function (as measured by whole blood ex vivo LPS-induced TNF-alpha production capacity) is below a critical threshold, the subject will receive GM-CSF at a dose of 30, 62, or 125 mcg/m2 per day for three days. Enrollment is stratified by pubertal status (Tanner 1 or Tanner \> 1) and by presence or absence of severe traumatic brain injury (TBI). Dose-finding is being conducted independently in each of these strata. The outcome variable for the dose-finding phase of the GIFT study is restoration of TNF-alpha production capacity and monocyte HLA-DR expression by the end of treatment, persisting to post-trauma day 7. A subsequent randomized, placebo-controlled trial with nosocomial infection as the primary outcome variable is planned once dose-finding is complete. This study is being conducted by the NICHD's Collaborative Pediatric Critical Care Research Network (CPCCRN) with Nationwide Children's Hospital as the primary site. The study design information currently displayed on this site refers to the dose-finding phase of the project.
Women presenting at the study site for a prenatal visit, and who are ≤ 70 days' gestation, will be offered participation in the study. Efforts will also be made to recruit patients through physician or treating health care professional referral and advertisements. One hundred and fifty consenting women will be enrolled. Up to three additional study visits will be scheduled: At the enrollment, if an ultrasound-confirmed gestational age is not available in the woman's medical record, a transvaginal ultrasound will be performed. If the woman is 56-63 days gestation on the day of enrollment, she will be asked to return weekly until she reaches 71-77 days. If the woman is 64-70 days gestation, she will be asked to return weekly until she reaches 78-84 days. If the woman is less than 56 days gestation, she will be asked to return for the three research visits at the appropriate time to provide the urine samples and blood draws. Women will have one visit during each of their three assigned gestational age weeks. At each visit, women will provide a urine sample for an MLPT and have a blood draw to measure serum hCG.
A composition and method are provided for inhibition of vascular smooth muscle cell proliferation following injury to the endothelial cell lining of a blood vessel such as resulting from angioplasty, vascular bypass surgery or organ transplantation. The composition is a matrix such as a biodegradable hydrogel made of a synthetic polymer, protein or polysaccharide seeded with vascular endothelial cells which can be xenografts, allografts or autografts, or genetically engineered cells. Attachment of cells to the matrix can be enhanced by coating with collagen, laminin, fibronectin, fibrin, basement membrane components or attachment peptides. Biologically active compounds such as anti-inflammatory agents may also be contained in the matrix. In the method, the matrix containing endothelial cells is implanted in a patient at a site adjacent the injury such as by wrapping the matrix around the blood vessel. The endothelial cells secrete products that diffuse into surrounding tissue but do not migrate to the endothelial cell lining of the blood vessel. The endothelial cells may be obtained by biopsy of the patient into which the matrix is implanted and the cells can be cultured in the matrix in vitro and then implanted in vivo.
The Test of Adherence to Inhalers (TAI) Toolkit links an adherence measurement instrument (the TAI) to proven effective interventions for different causes of non-adherence to inhaled medication. This study aimed to assess the usability and feasibility of the TAI Toolkit in clinical practice. The TAI Toolkit was piloted in eight primary and secondary care settings. Each study site included 10 patients with asthma and/or COPD and suspected non-adherence. Healthcare professionals (HCPs) recorded clinical data and TAI Toolkit outcomes. Data on usability and feasibility were collected in semi-structured interviews and with the System Usability Score (SUS). Of the included patients, 81% were non-adherent, and sporadic non-adherence was the most common (69%). The TAI Toolkit was valued with a mean SUS-score of 85.9 by the HCPs. They found the toolkit to 'be visually attractive', 'easy-to-use' and 'give insight into patients' adherence', thereby offering good potential for its use in clinical practice.
NEW MATERIAL:A lignan derivative of the formula (R1 is OH, R2 is methyl or incorporate R1 to form methylene or R1 is methyl and R2 is H). EXAMPLE:Isoschizandrin. USE:Medicine, antiulcerative. It is used to treat gastric and duodenal ulcers. PREPARATION:Dried fruits of Schizandra chinensis Baill are subjected to extraction with lower hydrocarbon such as petroleum ether at moderate temperatures. The solvent is removed from the extract and the residue is suspended in water, subjected to steam distillation to remove the essential oil. The remaining non- essential oil fraction is subjected to repeated silica-gel chromatography for purification. The resultant fraction is chromatographed with a silica-gel thin layer, eluted with a solvent such as methanol and irradiated with an ultraviolet ray of 2536Angstrom  wavelength to give the compound of the formula where R1 is hydroxy and R2 is methyl.
PURPOSE:To provide a new acetylated iron-chitosan complex which has a high iron content, adsorbs a large amt. of phosphoric acid while hardly adsorbing protein, is hardly sol. in an acidic soln., and prevents the dissolution of iron even in an acidic soln. CONSTITUTION:An acetylated iron-chitosan complex is provided which is obtd. by acetylating an iron-chitosan complex in an anhydrous alcohol solvent. Adsorbents for adsorbing phosphoric acid and for blood perfusion, each contg. the complex as the active ingredient, are also provided.
Two regions of the gene for the HTLV-I envelope were expressed in Escherichia coli by use of the vector pJLA16. One corresponds to the carboxy-terminal region of the major envelope protein p46 and the other corresponds to the transmembrane protein p21E. Reactivity of the expressed protein with human sera was tested by Western blot procedure. Each of the sera tested that had been shown to contain anti-HTLV-I or anti-HTLV-II antibodies by ELISA assay recognized the bacterially synthesized envelope proteins. There was no reaction detected when control sera were tested. This system is useful for large scale seroepidemiological surveys for this and related human retroviruses.
The purpose of this project was to isolate recombinant antibodies for diagnosis of very virulent infectious bursal disease virus (vvIBDV) in fixed tissues. Phage-displayed recombinant antibodies, comprised of the single chain variable fragment (scFv), were investigated. A previously made recombinant antibody library generated against vvIBDV was selected and screened for recombinant antibodies that reacted against vvIBDV in ELISA. A new library was constructed fom chickens immunized with fixed vvIBDV and also screened for recombinant antibodies against vvIBDV. Also, a previously identified recombinant antibody, known to react well with vvIBDV, was used to replace either the Vh or VI gene with corresponding fragments from a new library. The Vh and VI antibody genes were initially amplified effectively by PCR. No new recombinant antibody clones were isolated from the libraries generated against vvIBDV. However, exchanging the Vh or VI genes from a known recombinant antibody with genes from a new library showed that the heavy chain was essential when binding to vvBDV. Light chains could be exchanged without loss of activity, but when heavy chains were exchanged, all activity was lost. The light chains were found to create new binding properties when combined with the essential heavy chain. The recombinant antibody clones were sequenced, analyszd and characterize.
PURPOSE:To obtain the titled powder having the form of short filaments, free from coagulating tendency, and useful as a base of cosmetics, etc., by heating silk yarn etc. with saturated or superheated steam under pressure, releasing the yarn rapidly to a low-pressure atmosphere, and drying and pulverizing the expanded yarn. CONSTITUTION:Silk yarn, etc. (e.g. cocoon, waste cocoon, raw silk, silk fabric, etc.) is, if necessary immersed in hot water, hot water containing soap, sodium carbonate, etc., or warm water containing surface active agent and enzyme to remove the sericin component, and treated with saturated steam under a pressure of preferably 6-13kg/cm<2>G or with superheated steam under a pressure of preferably 5-13kg/cm<2>G at 160-240 deg.C usually for >=10min. The steam-treated silk is released to a low-pressure atmosphere, and the expanded product is dried and made easily pulverizable, and pulverized e.g. with a hammer mill to a fiber length of 30-50mu to obtain the objective powder.
Studies of spasmodic dysphonia (SD) have increasingly pointed to the possibility of a central sensori-motor control disorder. Sensori-motor processing has been found abnormal in both adductor and abductor spasmodic dysphonia based on reflex conditioning studies. These studies demonstrated an increased frequency of R2 muscle responses during rapid paired presentation of electrical stimuli to the superior laryngeal nerve in spasmodic dysphonia. Thus, uncontrolled R2 responses were hypothesized to be the basis for the uncontrolled muscle bursts in these patients. Selective suppression of late R2 laryngeal adductor responses by N-methyl-D-Aspartate (NMDA) blockade in cats was demonstrated by Ambalavanar et.al. In particular, dextromethorphan reduced the frequency of R2 responses from 95% to 25% (P = 0.015). Dextromethorphan is a widely used antitussive agent that has been in use for over 30 years. In a double-blind randomized crossover design, 3 groups of patients will receive be randomly assigned to one of 6 order cohorts. They will then receive either dextromethorphan at a 8 mg/kg/d dose divided in a Q6 hour dosing schedule with only 3 doses administered PO every 6 hours for 3 dosages, 04 mg/kg/d of lorazepam PO every 6 hours for 3 dosages or a placebo administrated in the same way during Phase A. After a minimum of a 1-week washout interval, the patients will be given either the other medication or placebo during Phase B and then the remaining medication or placebo during Phase C.

Our hypothesis is that dextromethorphan, an NMDA receptor blocker, will reduce voice breaks in spasmodic dysphonia to a greater degree than lorazepam, which has similar sedating side effects, but does not affect NMDA receptors with a different mechanism. On the other hand, patients with other idiopathic voice disorders, muscular tension dysphonia and vocal tremor, are hypothesized not to have a similar benefit from dextromethorphan. During the double-blind randomized cross-over study, three groups will be included, 10 patients with adductor or abductor spasmodic dysphonia, 10 with muscular tension dysphonia and 10 with vocal tremor. The results will determine if dextromethorphan has potential as a treatment option for patients with adductor or abductor SD.
The invention discloses a medicine for treating hypertension, which is an over-the-counter medicine for treating circulatory system diseases. It can be used for treating essential hypertension. Can reduce blood pressure to desired level. The medicine of the present invention is prepared with 7 kinds of Chinese medicinal materials, including gynostemma pentaphylla, red sage, etc. and through conventional process, and may be prepared into film coated tablet, hard capsule or sugar-free granule for oral taking. It has the actions of nourishing yin, suppressing yang hyperactivity, calming endogenous wind, resolving phlegm, purging pathogenic fire, removing blood stasis, etc., and is especially suitable for patients with severe hyperactivity of liver yang or hyperactivity of yin-deficiency and yang. Can timely, durably, stably and moderately reduce blood pressure, and symptoms such as hypertension accompanied with insomnia, giddiness, headache, cardiopalmus, tinnitus, constipation and limb numbness can be eliminated as soon as possible, target organs such as heart, brain, kidney and retina can be prevented from being damaged, and risk factors can be eliminated. Can be used for regulating and treating functional metabolism disorder such as blood lipid, blood sugar, blood viscosity, etc. complicated with hypertension. Solves the problem that no specific medicine is available for treating hypertension at present.
Participants randomized to this arm will receive pedometers plus a weekly prompt to set a step goal. They will participate in baseline and 3 months data collection.
Monitored pharmaceutical components, systems, and methods are described. The monitored pharmaceutical components include a body and electronics within the body. The electronics can detect forces acting on the monitored pharmaceutical component, generate data indicative of the forces over time, and transmit the data. The systems can also include a plurality of unmonitored pharmaceutical components. Each unmonitored pharmaceutical component can include a body that substantially corresponds to the body of the monitored pharmaceutical component. The system can also include a device external from the monitored pharmaceutical component. The device can receive, from the electronics of the monitored pharmaceutical component, the data. The device can predict, based on the data indicative of the forces acting on the monitored pharmaceutical component over time, degradation of the plurality of unmonitored pharmaceutical components.
The patients who have suffered an acute coronary event have a recurrence rate of 2.5% to 15.5% person-years during the first year. Control of cardiovascular risk factors can improve the prognosis of these patients. Following the results of a clinical trial to validate a comprehensive monitoring system called Cardioplan, with a prolonged monitoring strategy, The investigators aim to conduct a study in patients with chronic coronary syndrome in the primary care setting comparing a control group with standard follow-up and a 10-month telemonitored group. Four primary care centres will participate. Two health centres attend mainly a population with a medium-high upper socioeconomic level and the other two mainly a population with a medium-low socioeconomic level. A total of 160 subjects are expected to be included in the follow-up, with 80 subjects in each study group. The primary endpoint is to demonstrate that telemonitored follow-up improves functional exercise capacity compared to usual care, by assessing the distance in meters covered in the 6-minute walk test.